DexCom (DXCM) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

DXCM Stock Forecast


DexCom (DXCM) stock forecast, based on 52 Wall Street analysts, predicts a 12-month average price target of $84.00, with a high of $95.00 and a low of $64.00. This represents a 11.63% increase from the last price of $75.25.

$60 $76 $92 $108 $124 $140 High: $95 Avg: $84 Low: $64 Last Closed Price: $75.25

DXCM Stock Rating


DexCom stock's rating consensus is Buy, based on 52 Wall Street analysts. The breakdown includes 1 Strong Buy (1.92%), 41 Buy (78.85%), 8 Hold (15.38%), 2 Sell (3.85%), and 0 Strong Sell (0.00%).

Buy
Total 52 2 8 41 1 Strong Sell Sell Hold Buy Strong Buy

DXCM Price Target Upside V Benchmarks


TypeNameUpside
StockDexCom11.63%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks32.91%

Price Target Trends


1M3M12M
# Anlaysts61232
Avg Price Target$84.50$82.25$83.69
Last Closing Price$75.25$75.25$75.25
Upside/Downside12.29%9.30%11.22%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 263213--27
May, 264202-127
Apr, 264202-127
Mar, 265203-129
Feb, 265203-129
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2026UBS$95.00$78.4221.14%26.25%
Jun 09, 2026Anthony PetroneMizuho Securities$85.00$76.6210.94%12.96%
Jun 08, 2026Raymond James$91.00$76.6218.77%20.93%
Jun 05, 2026Jonathan BlockStifel Nicolaus$90.00$72.5923.98%19.60%
May 18, 2026Canaccord Genuity$82.00$61.6333.05%8.97%
May 18, 2026Matt MiksicBarclays$64.00$61.633.85%-14.95%
May 01, 2026Bernstein$77.00$61.0326.17%2.33%
May 01, 2026Robert W. Baird$80.00$61.8329.39%6.31%
May 01, 2026Anthony PetroneMizuho Securities$75.00$61.6521.65%-0.33%
May 01, 2026Raymond James$81.00$59.5536.02%7.64%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2026Cowen & Co.BuyBuyhold
Jun 08, 2026Raymond JamesStrong BuyStrong Buyhold
May 28, 2026CitigroupBuyBuyhold
May 18, 2026BarclaysUnderweightUnderweighthold
May 11, 2026BenchmarkBuyinitialise
May 04, 2026CitigroupBuyBuyhold
Feb 13, 2026BarclaysUnderweightUnderweighthold
Feb 05, 2026Piper SandlerOverweightOverweighthold
Jan 12, 2026Morgan StanleyOverweightOverweighthold
Jan 12, 2026BarclaysEqual-WeightUnderweightdowngrade

Financial Forecast


EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.56$0.88$1.44$1.46$2.14---
Avg Forecast$0.71$0.80$1.44$1.69$2.02$2.45$3.11$3.85
High Forecast$0.73$0.81$1.48$1.74$2.19$2.77$3.26$3.89
Low Forecast$0.69$0.78$1.40$1.60$1.79$2.01$2.95$3.82
Surprise %-21.13%10.00%--13.61%5.94%---

Revenue Forecast

$2B $3B $4B $5B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.45B$2.91B$3.62B$4.03B$4.66B---
Avg Forecast$2.45B$2.91B$3.60B$4.02B$4.61B$5.31B$6.26B$7.15B
High Forecast$2.50B$2.93B$3.63B$4.03B$4.65B$5.31B$6.30B$7.21B
Low Forecast$2.41B$2.87B$3.58B$4.00B$4.59B$5.30B$6.22B$7.11B
Surprise %-0.00%0.16%0.56%0.27%1.15%---

Net Income Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$216.90M$341.20M$541.50M$576.20M$836.30M---
Avg Forecast$108.96M$212.70M$541.50M$680.80M$779.93M$954.91M$1.32B$1.64B
High Forecast$140.14M$265.56M$676.08M$739.43M$931.55M$1.18B$1.39B$1.65B
Low Forecast$77.78M$159.84M$406.92M$679.93M$759.83M$856.02M$1.26B$1.63B
Surprise %99.06%60.41%--15.36%7.23%---

DXCM Forecast FAQ


Is DexCom stock a buy?

DexCom stock has a consensus rating of Buy, based on 52 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 41 Buy, 8 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that DexCom is a favorable investment for most analysts.

What is DexCom's price target?

DexCom's price target, set by 52 Wall Street analysts, averages $84 over the next 12 months. The price target range spans from $64 at the low end to $95 at the high end, suggesting a potential 11.63% change from the previous closing price of $75.25.

How does DexCom stock forecast compare to its benchmarks?

DexCom's stock forecast shows a 11.63% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the medical device stocks industry (32.91%).

What is the breakdown of analyst ratings for DexCom over the past three months?

  • June 2026: 11.11% Strong Buy, 77.78% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 14.81% Strong Buy, 74.07% Buy, 7.41% Hold, 0% Sell, 3.70% Strong Sell.
  • April 2026: 14.81% Strong Buy, 74.07% Buy, 7.41% Hold, 0% Sell, 3.70% Strong Sell.

What is DexCom’s EPS forecast?

DexCom's average annual EPS forecast for its fiscal year ending in December 2026 is $2.45, marking a 14.49% increase from the reported $2.14 in 2025. Estimates for the following years are $3.11 in 2027, and $3.85 in 2028.

What is DexCom’s revenue forecast?

DexCom's average annual revenue forecast for its fiscal year ending in December 2026 is $5.31B, reflecting a 13.85% increase from the reported $4.66B in 2025. The forecast for 2027 is $6.26B, and $7.15B for 2028.

What is DexCom’s net income forecast?

DexCom's net income forecast for the fiscal year ending in December 2026 stands at $954.91M, representing an 14.18% increase from the reported $836.3M in 2025. Projections indicate $1.32B in 2027, and $1.64B in 2028.